{
    "nct_id": "NCT04699188",
    "official_title": "A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
    "inclusion_criteria": "* Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies\n* ECOG Performance Status of 0 or 1\n* At least one measurable lesion as defined by RECIST 1.1\n* Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations\n* Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible\n* Clinically significant cardiac disease or risk factors at screening\n* A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}